Norris JS - Search Results

1

A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity.

Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL, Norris JS, Meyn RE, McDonnell TJ. Honda T, et al. Among authors: norris js. Cancer Biol Ther. 2002 Mar-Apr;1(2):163-7. doi: 10.4161/cbt.63. Cancer Biol Ther. 2002. PMID: 12170776

2

Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.

Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Lowe SL, et al. Among authors: norris js. Gene Ther. 2001 Sep;8(18):1363-71. doi: 10.1038/sj.gt.3301531. Gene Ther. 2001. PMID: 11571575

3

The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer.

Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY. Norris JS, et al. Curr Gene Ther. 2001 May;1(1):123-36. doi: 10.2174/1566523013348977. Curr Gene Ther. 2001. PMID: 12109135 Review.

4

Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.

Rubinchik S, Lowe S, Jia Z, Norris J, Dong J. Rubinchik S, et al. Gene Ther. 2001 Feb;8(3):247-53. doi: 10.1038/sj.gt.3301364. Gene Ther. 2001. PMID: 11313797

5

Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.

Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS. Hyer ML, et al. Among authors: norris js. Cancer Biol Ther. 2002 Jul-Aug;1(4):401-6. doi: 10.4161/cbt.1.4.15. Cancer Biol Ther. 2002. PMID: 12432255

6

Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.

Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel-Johnson C, Liu X. Norris JS, et al. Among authors: norris k. Cancer Gene Ther. 2006 Dec;13(12):1045-51. doi: 10.1038/sj.cgt.7700965. Epub 2006 Jun 9. Cancer Gene Ther. 2006. PMID: 16763610 Review.

7

Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.

Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS. Hyer ML, et al. Among authors: norris js. Cancer Gene Ther. 2003 Apr;10(4):330-9. doi: 10.1038/sj.cgt.7700576. Cancer Gene Ther. 2003. PMID: 12679806

8

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

Voelkel-Johnson C, King DL, Norris JS. Voelkel-Johnson C, et al. Among authors: norris js. Cancer Gene Ther. 2002 Feb;9(2):164-72. doi: 10.1038/sj.cgt.7700420. Cancer Gene Ther. 2002. PMID: 11857034

9

Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells.

Huang Y, Johnson KR, Norris JS, Fan W. Huang Y, et al. Among authors: norris js. Cancer Res. 2000 Aug 15;60(16):4426-32. Cancer Res. 2000. PMID: 10969788

10

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.

Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. Sudarshan S, et al. Among authors: norris js. Cancer Gene Ther. 2005 Jan;12(1):12-8. doi: 10.1038/sj.cgt.7700746. Cancer Gene Ther. 2005. PMID: 15514684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

151 results

Search Page